Trials / Not Yet Recruiting
Not Yet RecruitingNCT07234032
An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
A Long-term Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder for Treatment of Pulmonary Hypertension Associated With Interstitial Lung Disease
- Status
- Not Yet Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 344 (estimated)
- Sponsor
- Insmed Incorporated · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to evaluate the safety and tolerability of the long-term use of TPIP in participants with PH-ILD from Study INS1009-311 (NCT07179380).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Treprostinil Palmitil Inhalation Powder | Oral inhalation using a capsule-based dry powder. |
| DRUG | Placebo | Oral inhalation in initial double-dummy titration period. |
Timeline
- Start date
- 2026-04-01
- Primary completion
- 2031-01-22
- Completion
- 2031-01-22
- First posted
- 2025-11-18
- Last updated
- 2025-11-18
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07234032. Inclusion in this directory is not an endorsement.